Will novel agents for ALL finally change the natural history?

Best Practice and Research: Clinical Haematology

Volumn 27, Issue 3-4, 2014, Pages 247-258

  Douer, Dan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

acute lymphoblastic leukemia; ALL; CAR T cells; immunotherapy; targeted agents

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; BLINATUMOMAB; CHIMERIC ANTIGEN RECEPTOR; CLOFARABINE; CYTOKINE RECEPTOR LIKE FACTOR 2; JANUS KINASE; MONOCLONAL ANTIBODY; NELARABINE; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW APLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE SYNDROME; DISEASE COURSE; DNA MODIFICATION; HUMAN; LEUKEMIA RELAPSE; MEDICAL HISTORY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; CHILD; DRUG DELIVERY SYSTEM; FEMALE; GENETICS; LYMPHOCYTE TRANSFUSION; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG DELIVERY SYSTEMS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES;

EID: 84923854397     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2014.10.006     Document Type: Review

References (60)

1. R. Bassan, and D. Hoelzer Modern therapy of acute lymphoblastic leukemia J Clin Oncol 29 2011 532 543
2. J.M. Rowe Interpreting data on transplant selection and outcome in adult acute lymphoblastic leukemia (ALL) Biol Blood Marrow Transpl 17 2011 S76 S83
3. J.C. Alvarnas, P.A. Brown, and P. Aoun Acute lymphoblastic leukemia J Natl Compr Canc Netw 10 2012 858 914
4. R. Woodruff The management of adult acute lymphoblastic leukaemia Cancer Treat Rev 5 1978 95 113
5. R.A. Larson, R.K. Dodge, and C.P. Burns A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811 Blood 85 1995 2025 2037
6. J.M. Rowe, G. Buck, and A.K. Burnett Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 Blood 106 2005 3760 3767
7. A.J. Gottlieb, V. Weinberg, and R.R. Ellison Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B Blood 64 1984 267 274
8. W. Stock, J.L. Johnson, and R.M. Stone Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802 Cancer 119 2013 90 98
9. N. Gokbuget, R. Arnold, and T. Buechner Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93 Blood 98 2001 802a-802b [abstr 3337]
10. A.H. Goldstone, S.M. Richards, and H.M. Lazarus In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood 111 2008 1827 1833
11. C. Linker, L. Damon, and C. Ries Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia J Clin Oncol 20 2002 2464 2471
12. M.A. Weiss, L. Heffner, and M. Kalaycio A randomized trial demonstrating the superiority of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL J Clin Oncol 23 2005 6516 [abstr]
13. H. Kantarjian, D. Thomas, and S. O'Brien Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia Cancer 101 2004 2788 2801
14. K. Morris, H. Weston, and P. Mollee Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population Leuk Lymphoma 52 2011 85 91
15. W. Stock, M. La, and B. Sanford What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Blood 112 2008 1646 1654
16. J.M. Ribera, A. Oriol, and M.A. Sanz Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96 J Clin Oncol 26 2008 1843 1849
17. N. Gokbuget, J. Beck, and K. Brandt Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; Results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group for Adult ALL (GMALL) Blood (ASH Annual Meeting) 122 2013 839 [abstr]
18. A.S. Advani, B. Sanford, and S. Luger Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a peditric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance) Blood (ASH Annual Meeting) 122 2013 3903 [abstr]
19. D. Thomas, S. O'Brien, and S. Faderl Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen Cancer 116 2010 4580 4589
20. D. Douer, I. Aldoss, and M.A. Lunning Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia J Clin Oncol 32 2014 905 911
21. D. Douer Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol 21 2008 647 658
22. A. Pession, M.G. Valsecchi, and G. Masera Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia J Clin Oncol 23 2005 7161 7167
23. W. Stock, D. Douer, and D.J. DeAngelo Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel Leuk Lymphoma 52 2011 2237 2253
24. F. Huguet, T. Leguay, and E. Raffoux Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study J Clin Oncol 27 2009 911 918
25. D.J. DeAngelo, S. Dahlberg, and L.B. Silverman A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia Blood 110 2007 181a [abstr 587]
26. K. Nguyen, M. Devidas, and S.C. Cheng Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study Leukemia 22 2008 2142 2150
27. S. Jeha, P.S. Gaynon, and B.I. Razzouk Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia J Clin Oncol 24 2006 1917 1923
28. D.J. DeAngelo, D. Yu, and J.L. Johnson Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B Study 19801 Blood 109 2007 5136 5142
29. S. O'Brien, G. Schiller, and J. Lister High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia J Clin Oncol 31 2013 676 683
30. W.L. Salzer, B. Asselin, and J.G. Supko Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group Blood 122 2013 507 514
31. E.H. Panosyan, N.L. Seibel, and S. Martin-Aragon Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961 J Pediatr Hematol Oncol 26 2004 217 226
32. R.J. Brentjens CARs and cancers: questions and answers Blood 119 2012 3872 3873
33. R.J. Brentjens, I. Riviere, and J.H. Park Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 118 2011 4817 4828
34. S.A. Grupp, N.V. Frey, and R. Aplenc T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GvHD in children and adults with relapsed, refractory ALL Blood (ASH Annual Meeting) 122 2013 67 [abstr]
35. D.W. Lee III, N.N. Shah, and M. Stetler-Stevenson Anti-CD19 chimeric antigen receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell aplasia in children with relapsed or refractory acute lymphoblastic leukemia (ALL) even after allogeneic hematopoietic stem cell transplantation (HSCT) Blood (ASH Annual Meeting) 122 2013 68 [abstr]
36. M.L. Davila, I. Riviere, and X. Wang Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 2014 224ra25
37. D. Nagorsen, and P.A. Baeuerle Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab Exp Cell Res 317 2011 1255 1260
38. M.S. Topp, P. Kufer, and N. Gokbuget Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J Clin Oncol 29 2011 2493 2498
39. M. Topp, N. Goekbuget, and G. Zugmaier Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL J Clin Oncol 30 2012 6500 [abstr]
40. M.S. Topp, N. Gokbuget, and G. Zugmaier Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Blood 120 2012 5185 5187
41. M.S. Topp, N. Goekbuget, and A.S. Stein Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) J Clin Oncol 32 2014 7005 [abstr]
42. D. Hoelzer, A. Huettmann, and F. Kaul Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; Results of 263 CD20+ patients studied prospectively in GMALL study 07/2003 Blood 116 2010 170 [abstr]
43. D.A. Thomas, S. Faderl, and S. O'Brien Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia Cancer 106 2006 1569 1580
44. E.A. Raetz, M.S. Cairo, and M.J. Borowitz Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study J Clin Oncol 26 2008 3756 3762
45. D.J. DeAngelo, W. Stock, and A.R. Shustov Weekly inotuzumab ozogamicin (InO) in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) Blood (ASH Annual Meeting) 122 2013 3906 [abstr]
46. H. Kantarjian, D. Thomas, and J. Jorgensen Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Lancet Oncol 13 2012 403 411
47. C.G. Mullighan Molecular genetics of B-precursor acute lymphoblastic leukemia J Clin Invest 122 2012 3407 3415
48. K. Paulsson, J.B. Cazier, and F. Macdougall Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease Proc Natl Acad Sci U S A 105 2008 6708 6713
49. A.T. Nguyen, O. Taranova, and J. He DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis Blood 117 2011 6912 6922
50. S.R. Daigle, E.J. Olhava, and C.A. Therkelsen Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor Cancer Cell 20 2011 53 65
51. P. Van Vlierberghe, and A. Ferrando The molecular basis of T cell acute lymphoblastic leukemia J Clin Invest 122 2012 3398 3406
52. R.C. Harvey, C.G. Mullighan, and I.M. Chen Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia Blood 115 2010 5312 5321
53. C.G. Mullighan New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice Clin Cancer Res 17 2011 396 400
54. A.V. Moorman, C. Schwab, and H.M. Ensor IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia J Clin Oncol 30 2012 3100 3108
55. M.L. Loh, R.C. Harvey, and C.G. Mullighan A BCR-ABL1-like gene expression profile confers a poor prognosis in patients with high-risk acute lymphoblastic leukemia (HR-ALL): a report from Children's Oncology Group (COG) AALL0232 Blood (ASH Annual Meeting) 118 2011 743 [abstr]
56. P. Saunders, A. Cisterne, and J. Weiss The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia Haematologica 96 2011 69 77
57. P. Neviani, R. Santhanam, and J.J. Oaks FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia J Clin Invest 117 2007 2408 2421
58. E.G. Jeong, M.S. Kim, and H.K. Nam Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers Clin Cancer Res 14 2008 3716 3721
59. W. Deenik, H.B. Beverloo, and S.C. van der Poel-van de Luytgaarde Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia Leukemia 23 2009 627 629
60. N. Goekbuget, A. Baumann, and J. Beck PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003 Blood (ASH Annual Meeting) 116 2010 494 [abstr]